Prostate cancer is the second most common cancer in men, and prognosis varies with age, ethnicity, genetic background, and stage of progression. Disease progression that has been observed in a substantial proportion of patients despite androgen ablation, can arise from many factors, such as the presence of cells that are resistant de novo or acquire resistance induced by androgen-deprivation therapy (ADT) or androgen receptor antagonists.
However, the underlying molecular mechanisms are under ongoing investigation. Research into the molecular characterisation of localised, recurrent, and progressive disease will undoubtedly have an impact on clinical management. Similarly, emerging research into novel therapeutics, such as targeted radioisotopes and immunotherapy, holds much promise for improving the lives of patients with prostate cancer.
In addition to standard measures, it is crucial to identify new tools to classify the patients into high and low risk of disease progression under ADT and to develop risk-adapted and patient-oriented treatments. To achieve this aim, new technological investigations are needed to better understand the genetic/biology background of both localized and metastatic diseases and identify new biomarkers to recognize more aggressive tumors. The final objective is to use the new knowledge to develop a precision medicine approach, leading to improving the clinical outcome of the disease.
The goal of this special issue is to shed light on the advances and new findings on cancer prostate development, progression and treatment.
Submissions may address, but are not limited to, the following:
- Development of in vitro and in vivo models to elucidate the molecular mechanisms involved in drug resistance of prostate cancer
- Research progress of hormone therapy for prostate cancer
- New therapeutic targets for advanced prostate cancer
- New predictors for the aggressiveness and prostate cancer progression
- Genetic susceptibility and prostate cancer progression
The editors welcome original research, reviews and other accepted article types.
Prostate cancer is the second most common cancer in men, and prognosis varies with age, ethnicity, genetic background, and stage of progression. Disease progression that has been observed in a substantial proportion of patients despite androgen ablation, can arise from many factors, such as the presence of cells that are resistant de novo or acquire resistance induced by androgen-deprivation therapy (ADT) or androgen receptor antagonists.
However, the underlying molecular mechanisms are under ongoing investigation. Research into the molecular characterisation of localised, recurrent, and progressive disease will undoubtedly have an impact on clinical management. Similarly, emerging research into novel therapeutics, such as targeted radioisotopes and immunotherapy, holds much promise for improving the lives of patients with prostate cancer.
In addition to standard measures, it is crucial to identify new tools to classify the patients into high and low risk of disease progression under ADT and to develop risk-adapted and patient-oriented treatments. To achieve this aim, new technological investigations are needed to better understand the genetic/biology background of both localized and metastatic diseases and identify new biomarkers to recognize more aggressive tumors. The final objective is to use the new knowledge to develop a precision medicine approach, leading to improving the clinical outcome of the disease.
The goal of this special issue is to shed light on the advances and new findings on cancer prostate development, progression and treatment.
Submissions may address, but are not limited to, the following:
- Development of in vitro and in vivo models to elucidate the molecular mechanisms involved in drug resistance of prostate cancer
- Research progress of hormone therapy for prostate cancer
- New therapeutic targets for advanced prostate cancer
- New predictors for the aggressiveness and prostate cancer progression
- Genetic susceptibility and prostate cancer progression
The editors welcome original research, reviews and other accepted article types.
